Elda Araceli Mayorga

Elda Araceli Mayorga


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
LÁLorena Ávila-Carrasco
Lorena Ávila-Carrasco
EMElda Araceli Mayorga
Elda Araceli Mayorga
DDDaisy L. Díaz-Avila
Daisy L. Díaz-Avila
IGIdalia Garza-Veloz
Idalia Garza-Veloz
Margarita L. Martinez-FierroMargarita L. Martinez-Fierro
Margarita L. Martinez-Fierro
GGGuadalupe Tirma González-Mateo
Guadalupe Tirma González-Mateo
Background: The blockade of the progression or onset of pathological events is essential for the homeostasis of an organism. Some common pathological mechanisms involving a wide range of diseases are the uncontrolled inflammatory reactions that promote fibrosis, oxidative reactions, and other alterations. Natural plant compounds (NPCs) are bioactive elements obtained from natural sources that can regulate physiological processes. Inflammation is recognized as an important factor in the development and evolution of chronic renal damage. Consequently, any compound able to modulate inflammation or inflammation-related processes can be thought of as a renal protective agent and/or a potential treatment tool for controlling renal damage. The objective of this research was to review the beneficial effects of bioactive natural compounds on kidney damage to reveal their efficacy as demonstrated in clinical studies. Methods: This systematic review is based on relevant studies focused on the impact of NPCs with therapeutic potential for kidney disease treatment in humans. Results: Clinical studies have evaluated NPCs as a different way to treat or prevent renal damage and appear to show some benefits in improving OS, inflammation, and antioxidant capacity, therefore making them promising therapeutic tools to reduce or prevent the onset and progression of KD pathogenesis. Conclusions: This review shows the promising clinical properties of NPC in KD therapy. However, more robust clinical trials are needed to establish their safety and therapeutic effects in the area of renal damage.